#### **Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims**

Claim 1 (original) A compound of the formula I:

$$\begin{array}{c|c}
 & R^2 \\
 & M \\
 & N \\
 & N$$

wherein:

R<sup>1</sup> is selected from the group consisting of:

R<sup>2</sup> is selected from the group consisting of:

- $R^{4}-S(O)_{m}-NR^{5}-$ (1)
- $R^4$ -S(O)<sub>m</sub>-, (2)
- R<sup>4</sup>NHCO-, (3)
- R<sup>4</sup>CONH-, (4)
- R4R5N-, (5)
- (6) nitrile,
- NC- C<sub>1.6</sub>alkyl-, (7)
- (8) halogen,
- (9)

$$\mathbb{R}^{8a}$$
  $\mathbb{R}^{8b}$  , and

(10)

# $R^3$ is selected from the group consisting of:

$$R^{6c}$$
 $R^{6b}$ 
 $R^{6a}$ 
 $R^{4}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6b}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6a}$ 
 $R^{6a}$ 

R<sup>4</sup> is selected from the group consisting of:

- hydrogen, (1)
- C<sub>1-6</sub>alkyl, (2)
- phenyl, and (3)
- (4) benzyl;

R<sup>5</sup> is independently selected from the group consisting of:

- hydrogen; (1)
- $C_{1-6}$ alkyl, (2)
- (3) phenyl,
- benzyl, and (4)

R6a, R6b, and R6c are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3)  $-OR^5$ ,
- -SR<sup>5</sup>, and (4)
- (5) C<sub>1-6</sub>alkyl;

R<sup>7</sup> is selected from the group consisting of -C=C-, O, S, and NH;

Z is selected from the group consisting of CO, CH-OH, CH-F and



R<sup>8a</sup> and R<sup>8b</sup> are independently selected from the group consisting of:

- (1) nitrile
- (2) hydrogen,
- (3) halogen,
- $-OR^5$ , (4)
- -SR<sup>5</sup>, (5)
- C<sub>1-6</sub>alkyl, (6)
- -CO<sub>2</sub>R<sup>5</sup>, and (7)
- (8) tetrazolyl;

 $X^1$  is hydrogen and  $X^2$  is hydroxyl, or  $X^1$  and  $X^2$  together form oxo;

n is independently 1, 2, 3, or 4;

m is independently 0, 1, or 2;

and pharmaceutically acceptable salts thereof.

Claim 2 (Original) The compound of Claim 1 wherein X<sup>1</sup> and X<sup>2</sup> together form oxo.

Claim 3 (Original) The compound of Claim 1 wherein X<sup>1</sup> is hydrogen and X<sup>2</sup> is hydroxyl.

Claim 4 (Original) The compound of Claim 1 wherein R<sup>1</sup> is:

and wherein:

n is 2 or 3; and

R<sup>5</sup> is hydrogen or methyl;

and pharmaceutically acceptable salts thereof.

Claim 5 (Original) The compound of Claim 1 wherein R1 is:

$$S^{S^{2}}$$
 $N$ 
 $N$ 
 $N$ 
 $N$ 

and wherein n is 1, and pharmaceutically acceptable salts thereof.

Claim 6 (Original) The compound of Claim 1 wherein R1 is:

and wherein:

R<sup>5</sup> is hydrogen or methyl;

Z is selected from the group consisting of CO, CH-OH, and

and pharmaceutically acceptable salts thereof.

Claim 7 (Original) The compound of Claim 1 wherein R<sup>2</sup> is:

and wherein R<sup>4</sup> is selected from the group consisting of:

- (1) hydrogen,
- C<sub>1-6</sub>alkyl, (2)
- phenyl, and (3)
- (4) benzyl;

R<sup>5</sup> is selected from the group consisting of:

- C<sub>1-6</sub>alkyl, (1)
- (2) phenyl,
- (3) benzyl, and
- (4) hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 8 (Original) The compound of Claim 1 wherein  $R^3$  is:

and wherein:

R<sup>4</sup> is methyl;

R6a is H or F;

R6b and R6c are hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 9 (Original) The compound of Claim 1 wherein R<sup>3</sup> is:

wherein:

R<sup>5</sup> is methyl;

R<sup>7</sup> is O or NH;

### and pharmaceutically acceptable salts thereof.

Claim 10 (Original) The compound of Claim 2 which is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

# Claim 11 (Original) The compound of Claim 3 which is selected from the group consisting of:

Int'l Appl'n No.: PCT/US03/35316

Case No.: 21145YP Page No.: 11

and pharmaceutically acceptable salts thereof.

Claim 12 (Original) A compound of Claim 1 in substantially diastereomerically pure form.

Claim 13 (Original) A substantially diastereomerically pure compound of Claim 1 in substantially enantiomerically pure form.

Claim 14 (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 15 (Original) A method for inhibition of  $\square$ -secretase activity in a mammal which comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

Claim 16 (Cancelled)

Claim 17 (Original) A method for treating, preventing, controlling, ameliorating or reducing the risk of Alzheimers disease in a patient comprising the administration to the patient of a therapeutically effective amount of a compound of Claim 1.